Lindane
drugOn this page
Also known as Benzene hexachloride gammaBenzene hexachloridegammaEsodermGameneGamma benzene hexachlorideGammahexachlorcyclohexaneGamma benzene hydrochlorideGammallinGammaxeneGexaneHexachloraneHexicideKwellLindanoLindanumLorexaneLorexane no 3NSC-755895
Summary
Lindane (CHEMBL15891) is an approved small-molecule GABA-gated chloride channel antagonist (ATC P03AB02); indicated across 2 conditions including parasitic infectious disease and lice infestation.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: P03AB02
- Indications: 2 conditions
- Chemistry: 290.8 Da · C6H6Cl6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL15891 |
| Name | Lindane |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 727 |
| ChEBI | CHEBI:32888 |
| ATC | P03AB02 |
| Molecular formula | C6H6Cl6 |
| Molecular weight | 290.8 |
| InChIKey | JLYXXMFPNIAWKQ-UHFFFAOYSA-N |
SMILES: C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl
IUPAC name: 1,2,3,4,5,6-hexachlorocyclohexane
Pharmacological roles (ChEBI): GABA-gated chloride channel antagonist, rodenticide, agrochemical, fungicide, antibacterial agent, pediculicide, ectoparasiticide.
Other ChEBI roles (chemical / environmental): persistent organic pollutant.
Also known as: Benzene hexachloride gamma, Benzene hexachloride, gamma, Esoderm, Gamene, Gamma benzene hexachloride, Gammahexachlorcyclohexane, Gamma benzene hydrochloride, Gammallin, Gammaxene, Gexane, Hexachlorane
Patent coverage: 36,702 distinct patent families (83,653 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Gamma-aminobutyric acid receptor subunit beta-3, GABA-A receptor; alpha-1/beta-3/gamma-2, GABA-A receptor; alpha-6/beta-3/gamma-2, GABA A receptor alpha-1/beta-1/gamma-2, Androgen receptor, Gamma-aminobutyric acid receptor subunit rho-1, Gamma-aminobutyric acid receptor subunit alpha-1/ beta-1, Gamma-aminobutyric acid receptor subunit alpha-6/beta-3, GABA receptor subunit, GABA-A receptor alpha-1/beta-3.
Bioactivity
ChEMBL activities: 9 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| GABRB3 | 9.05 | IC50 | 0.9 | nM | CHEMBL_ACT_12563731 |
| GABRB3 | 8.89 | IC50 | 1.3 | nM | CHEMBL_ACT_12563728 |
| GABRG2 | 8.31 | IC50 | 4.9 | nM | CHEMBL_ACT_12563725 |
| Q75NA5 | 7.96 | IC50 | 11 | nM | CHEMBL_ACT_12563704 |
| GABRA1 | 7.92 | IC50 | 12 | nM | CHEMBL_ACT_12563722 |
| GABRA1 | 7.68 | IC50 | 21 | nM | CHEMBL_ACT_12563719 |
| GABRA1 | 7.17 | IC50 | 67 | nM | CHEMBL_ACT_12563713 |
| GABRR1 | 7.04 | IC50 | 91 | nM | CHEMBL_ACT_12563710 |
| GABRA1 | 6.95 | IC50 | 112 | nM | CHEMBL_ACT_12563716 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| parasitic infectious disease | 4 | MONDO:0005135 | EFO:0001067 |
| lice infestation | 2 | MONDO:0003472 | MONDO:0003472 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: parasitic infectious disease